Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational Study of Trastuzumab Emtansine (T-DM1) in Chinese HER2-Positive Advanced Breast Cancer
ChiCTR2300072900Phase 4Not yet recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab emtansine in breast cancer, sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2300072900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072900.